Following today’s press release from Spotlight, the company’s share will be moved to Spotlight’s Observation List. Information about the share: Shortname: EUCI ISIN-code: SE0001839069 Orderbook-ID: 4102 CFI: ESVUFR FISN: EUROCINE/SH Organization number: 556566-4298 LEI: 549300B408R6FTXR0D15 Stockholm January 15, 2019 Spotlight Stock Market 08-511 68 000 info@spotlightstockmarket.com
Category: In english
Following today’s press release from Spotlight, the company’s share will be moved to Spotlight’s Observation List. Information about the share: Shortname: EUCI ISIN-code: SE0001839069 Orderbook-ID: 4102 CFI: ESVUFR FISN: EUROCINE/SH Organization number: 556566-4298 LEI: 549300B408R6FTXR0D15 Stockholm January 15, 2019 Spotlight Stock Market 08-511 68 000 info@spotlightstockmarket.com
Eurocine Vaccines today announced good safety and tolerability in older adults, in the second clinical phase I/II study including their quadrivalent influenza vaccine candidate. Immunose™ FLU is a novel nose drop formulation based on the company’s technology Endocine™ and inactivated split influenza antigens. – I am very happy that we have once again confirmed good
– In the perspective of this year’s severe influenza outburst we are pleased to have chosen the broader quadrivalent, rather than trivalent, vaccine for our product candidate, says Dr. Anna-Karin Maltais, Chief Scientific Officer. -The elderly always suffer most from influenza disease and we believe that we can offer a better and more convenient vaccine
The purpose of the study is to evaluate safety, tolerability, as well as serological and mucosal immune responses against four influenza antigens in older adults aged 50-75. Recruitment of subjects is ongoing and about 300 subjects will be divided into seven treatment groups. The study is planned to be conducted at five locations throughout Sweden
Following up WVC in Washington during the spring CSO Anna-Karin Maltais and CEO Hans Arwidsson will present the latest progress from development of Immunose™ FLU, our first vaccine candidate, based on our technology platform Endocine™ This conference is about research, development and strategic partnering for the global vaccine industry. Read more here =>
One of the most important conferences in the North American vaccine industry is the annual WVC in Washington. Here, scientists and decision makers meet to discuss the latest innovation and development. Eurocine Vaccines´ CSO, Dr. Anna-Karin Maltais, will contribute with the latest results from our clinical study with Immunose™ FLU, our first product candidate based on
At least one executive from the Management Team of Eurocine Vaccines will be present at this partnering conference to meet and discuss the latest development in nasal vaccination and specifically present recent results from the clinical study with Immunose™ FLU – our first candidate based on the technology platform Endocine™. If you plan attending the conference
Eurocine Vaccines has been specially invited to speak at this years annual industry conference for investors of BioTech and Life Science on the topic “At the forefront of Nasal Vaccination” Please reach out to CEO Hans Arwidsson if you plan to attend the conference in order to book a meeting => What is Biotech and Money?
Eurocine Vaccines submitted applications to the Swedish Medical Products Agency, MPA, and to the Ethics Committee in early November. The Company announced today that authorizations to conduct the study have been received from both. – Our thoroughly prepared application and qualified dialogue with the Swedish MPA has yet again proven a success why our ambitious